Read more

February 27, 2020
1 min read
Save

Additional periarticular injection after TKA may provide postoperative pain relief

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Takuya Iseki headshot
Takuya Iseki

PHOENIX — Use of additional percutaneous periarticular multi-drug injection the day after total knee replacement may provide postoperative pain relief, according to results presented at the Orthopaedic Research Society Annual Meeting.

Takuya Iseki, MD and colleagues randomly assigned 43 patients undergoing unilateral TKA (Scorpio NRG-PS, Stryker Orthopaedics) to receive intraoperative, periarticular multi-drug injection with either an additional periarticular multi-drug injection 1 day after TKA or no additional injection. Researchers collected VAS pain score at rest, quantified the area under the curve and analyzed serial assessments until postoperative day 5 as the primary outcome. Secondary outcomes included VAS pain score during activity, consumption of rescue medication, complications and range of motion of the knee.

In his presentation, Iseki noted patients in the additional injection group had lower VAS scores at rest, as well as no elevation of VAS scores at rest.

“VAS scores during activity were measured during rehabilitation once a day, and [were] lower in the additional injection group than in the no injection group on days 1 and 3 postoperatively,” Iseki said.

He added the two groups had no significant differences in consumption of rescue medicine or range of motion for 5 days, and no wound complications or surgical site infections were found in either group. – by Casey Tingle

 

References:

Iseki T, et al. BMC Musculoskelet Disord. 2019;doi:10.1186/s12891-019-2451-1.

 

Iseki T, et al. Paper 178. Presented at: Orthopaedic Research Society Annual Meeting; Feb. 8-11, 2020; Phoenix.

 

Disclosure: Iseki reports no relevant financial disclosures.